Human Genome Epidemiology Literature Finder
Records 1 - 21 (of 21 Records) |
Query Trace: Melanoma and CTLA4[original query] |
---|
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. Journal of immunotherapy (Hagerstown, Md. : 1997) 0 31 (6): 586-90. Breunis Willemijn B, Tarazona-Santos Eduardo, Chen Renee, Kiley Maureen, Rosenberg Steven A, Chanock Stephen |
Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer immunology, immunotherapy : CII 2010 Feb 59 (2): 303-12. Bouwhuis Marna G, Gast Andreas, Figl Adina, Eggermont Alexander M M, Hemminki Kari, Schadendorf Dirk, Kumar Raj |
CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer research 2009 Aug 69 (15): 6158-63. Welsh Marleen M, Applebaum Katie M, Spencer Steven K, Perry Ann E, Karagas Margaret R, Nelson Heather |
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-a but Not Observation in Intermediate Risk Melanoma Patients. PloS one 2015 10 (7): e0132745. Tarhini Ahmad A, Lin Yan, Zahoor Haris, Shuai Yongli, Butterfield Lisa H, Ringquist Steven, Gogas Helen, Sander Cindy, Lee Sandra, Agarwala Sanjiv S, Kirwood John |
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nature genetics 2016 Sep . Riaz Nadeem, Havel Jonathan J, Kendall Sviatoslav M, Makarov Vladimir, Walsh Logan A, Desrichard Alexis, Weinhold Nils, Chan Timothy |
Genetic variation in IRF4 expression modulates growth characteristics, tyrosinase expression and interferon-gamma response in melanocytic cells. Pigment cell & melanoma research 2017 7 31 (1): 51-63. Chhabra Yash, Yong Hilary X L, Fane Mitchell E, Soogrim Arish, Lim Wen, Mahiuddin Dayana Nur, Kim Reuben S Q, Ashcroft Melinda, Beatson Scott A, Ainger Stephen A, Smit Darren J, Jagirdar Kasturee, Walker Graeme J, Sturm Richard A, Smith Aaron |
Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature communications 2017 10 8 (1): 1136. Sade-Feldman Moshe, Jiao Yunxin J, Chen Jonathan H, Rooney Michael S, Barzily-Rokni Michal, Eliane Jean-Pierre, Bjorgaard Stacey L, Hammond Marc R, Vitzthum Hans, Blackmon Shauna M, Frederick Dennie T, Hazar-Rethinam Mehlika, Nadres Brandon A, Van Seventer Emily E, Shukla Sachet A, Yizhak Keren, Ray John P, Rosebrock Daniel, Livitz Dimitri, Adalsteinsson Viktor, Getz Gad, Duncan Lyn M, Li Bo, Corcoran Ryan B, Lawrence Donald P, Stemmer-Rachamimov Anat, Boland Genevieve M, Landau Dan A, Flaherty Keith T, Sullivan Ryan J, Hacohen N |
Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers. Frontiers in immunology 2018 9 9 2012. Egg David, Schwab Charlotte, Gabrysch Annemarie, Arkwright Peter D, Cheesman Edmund, Giulino-Roth Lisa, Neth Olaf, Snapper Scott, Okada Satoshi, Moutschen Michel, Delvenne Philippe, Pecher Ann-Christin, Wolff Daniel, Kim Yae-Jean, Seneviratne Suranjith, Kim Kyoung-Mee, Kang Ji-Man, Ojaimi Samar, McLean Catriona, Warnatz Klaus, Seidl Maximilian, Grimbacher Bo |
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. European journal of cancer (Oxford, England : 1990) 2018 12 107 8-14. Hasan Ali Omar, Berner Fiamma, Bomze David, Fässler Mirjam, Diem Stefan, Cozzio Antonio, Jörger Markus, Früh Martin, Driessen Christoph, Lenz Tobias L, Flatz Luk |
Combined analysis of keratinocyte cancers identifies novel genome-wide loci.
Human molecular genetics 2019 09 28 (18): 3148-3160. Liyanage Upekha E, Law Matthew H, Han Xikun, An Jiyuan, Ong Jue-Sheng, Gharahkhani Puya, Gordon Scott, Neale Rachel E, Olsen Catherine M, , MacGregor Stuart, Whiteman David |
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature medicine 2019 12 25 (12): 1916-1927. Liu David, Schilling Bastian, Liu Derek, Sucker Antje, Livingstone Elisabeth, Jerby-Arnon Livnat, Zimmer Lisa, Gutzmer Ralf, Satzger Imke, Loquai Carmen, Grabbe Stephan, Vokes Natalie, Margolis Claire A, Conway Jake, He Meng Xiao, Elmarakeby Haitham, Dietlein Felix, Miao Diana, Tracy Adam, Gogas Helen, Goldinger Simone M, Utikal Jochen, Blank Christian U, Rauschenberg Ricarda, von Bubnoff Dagmar, Krackhardt Angela, Weide Benjamin, Haferkamp Sebastian, Kiecker Felix, Izar Ben, Garraway Levi, Regev Aviv, Flaherty Keith, Paschen Annette, Van Allen Eliezer M, Schadendorf Di |
TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment. Cancer medicine 2020 Aug . Li Huahua, Li Jia, Zhang Chenyue, Zhang Chenxing, Wang Haiyo |
Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma. Frontiers in immunology 2021 11 12 692079. Ma Ben, Jiang Hongyi, Luo Yi, Liao Tian, Xu Weibo, Wang Xiao, Dong Chuanpeng, Ji Qinghai, Wang |
Differential Expression of the TLR4 Gene in Pan-Cancer and Its Related Mechanism. Frontiers in cell and developmental biology 2021 10 9 700661. Hu Jialing, Xu Jiasheng, Feng Xiaojin, Li Yiran, Hua Fuzhou, Xu Guoh |
Clinical significance and immune landscape of KIR2DL4 and the senescence-based signature in cutaneous melanoma. Cancer science 2022 7 113 (11): 3947-3959. Mao Rui, Ren Zhengyun, Yang Fan, Yang Peng, Zhang Tongto |
Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment. Genes & genomics 2022 2 44 (4): 509-515. Yang Yohan, Kim Eunyoung, Kim Sangw |
Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma. Clinical & translational immunology 2023 8 12 (8): e1465. John Wen-Cheng Chang, Chien-Jung Huang, Wen-Kuan Huang, Yu-Chao Wang, Jia-Juan Hsieh, Yao-Yu Chang, Yen-Lin Huang, Chia-Ling Wu, Yeh-Han Wang, Shu-Jen Chen, Kien Thiam Tan, Chiao-Ping Chen, Chiao-En |
HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma. Aging 2023 8 15 . Liu Li, Kuang Tianrui, Li Chunlei, Qiu Zhendong, Chen Xiaoyan, Deng Wenho |
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. European journal of cancer (Oxford, England : 1990) 2023 5 188 140-151. Anne Zaremba, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Claudia Pföhler, Michael Weichenthal, Patrick Terheyden, Andrea Forschner, Ulrike Leiter, Jens Ulrich, Jochen Utikal, Julia Welzel, Martin Kaatz, Christoffer Gebhardt, Rudolf Herbst, Anca Sindrilaru, Edgar Dippel, Michael Sachse, Frank Meiss, Lucie Heinzerling, Sebastian Haferkamp, Carsten Weishaupt, Harald Löffler, Sophia Kreft, Klaus Griewank, Elisabeth Livingstone, Dirk Schadendorf, Selma Ugurel, Lisa Zimm |
Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study. Journal of dermatological science 2023 4 . Inozume Takashi, Namikawa Kenjiro, Kato Hiroshi, Yoshikawa Shusuke, Kiniwa Yukiko, Yoshino Koji, Mizuhashi Satoru, Ito Takamichi, Takenouchi Tatsuya, Matsushita Shigeto, Fujisawa Yasuhiro, Matsuzawa Takamitsu, Sugihara Satoru, Asai Jun, Kitagawa Hiroshi, Maekawa Takeo, Isei Taiki, Yasuda Masahito, Yamazaki Naoya, Uhara Hisashi, Nakamura Yasuhi |
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations. Cancers 2024 4 16 (7): . Alexandra M Haugh, Robert C Osorio, Rony A Francois, Michael E Tawil, Katy K Tsai, Michael Tetzlaff, Adil Daud, Harish N Vasudev |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: